Your browser doesn't support javascript.
COVID-19 vaccine effectiveness against severe disease from SARS-CoV-2 Omicron BA.1 and BA.2 subvariants - surveillance results from southern Sweden, December 2021 to March 2022.
Björk, Jonas; Bonander, Carl; Moghaddassi, Mahnaz; Rasmussen, Magnus; Malmqvist, Ulf; Inghammar, Malin; Kahn, Fredrik.
  • Björk J; Clinical Studies Sweden, Forum South, Skåne University Hospital, Lund, Sweden.
  • Bonander C; Division of Occupational and Environmental Medicine, Lund University, Lund, Sweden.
  • Moghaddassi M; School of Public Health and Community Medicine, Institute of Medicine, University of Gothenburg, Gothenburg, Sweden.
  • Rasmussen M; Social Medicine and Global Health, Department of Clinical Sciences Malmö, Lund University, Malmö, Sweden.
  • Malmqvist U; Department of Clinical Sciences Lund, Section for Infection Medicine, Skåne University Hospital, Lund University, Lund, Sweden.
  • Inghammar M; Division of Occupational and Environmental Medicine, Lund University, Lund, Sweden.
  • Kahn F; Department of Clinical Sciences Lund, Section for Infection Medicine, Skåne University Hospital, Lund University, Lund, Sweden.
Euro Surveill ; 27(18)2022 05.
Article in English | MEDLINE | ID: covidwho-1834267
ABSTRACT
We compared vaccine effectiveness against severe COVID-19 between December 2021 and March 2022 when Omicron BA.1 and BA.2 were the dominating SARS-CoV-2 variants in Scania county, Sweden. Effectiveness remained above 80% after the transition from BA.1 to BA.2 among people with at least three vaccine doses but the point estimate decreased markedly to 54% among those with only two doses. Protection from prior infection was also lower after the transition to BA.2. Booster vaccination seems necessary to maintain sufficient protection.
Subject(s)
Keywords
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: SARS-CoV-2 / COVID-19 Type of study: Experimental Studies / Observational study Topics: Vaccines / Variants Limits: Humans Country/Region as subject: Europa Language: English Journal subject: Communicable Diseases Year: 2022 Document Type: Article Affiliation country: 1560-7917.ES.2022.27.18.2200322

Similar

MEDLINE
LILACS
LIS
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: SARS-CoV-2 / COVID-19 Type of study: Experimental Studies / Observational study Topics: Vaccines / Variants Limits: Humans Country/Region as subject: Europa Language: English Journal subject: Communicable Diseases Year: 2022 Document Type: Article Affiliation country: 1560-7917.ES.2022.27.18.2200322